Analytical Data
-
Gene name
CD58
- Application
-
Alternative Names
CD58；LFA3；Lymphocyte function-associated antigen 3
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P19256
-
Expression Region
29-215aa
-
AA Sequence
FSQQIYGVVY GNVTFHVPSN VPLKEVLWKK QKDKVAELEN SEFRAFSSFK NRVYLDTVSG SLTIYNLTSS DEDEYEMESP NITDTMKFFL YVLESLPSPT LTCALTNGSI EVQCMIPEHY NSHRGLIMYS WDCPMEQCKR NSTSIYFKME NDLPQKIQCT LSNPLFNTTS SIILTTCIPS SGHSRHR
-
Molecular Weight
50 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CD58, also known as LFA-3 (Lymphocyte Function-Associated Antigen 3), is a crucial co-stimulatory molecule primarily expressed on antigen-presenting cells (APCs) and plays a significant role in the activation of T lymphocytes and the regulation of immune responses. The interaction between CD58 and CD2 on T cells is essential for effective immune signaling, influencing T cell proliferation, survival, and differentiation. Given its pivotal role in modulating immune responses, CD58 has drawn attention in various fields, including immunology, cancer research, and autoimmune diseases. Research has shown that CD58 can impact the efficacy of T cell-mediated responses in tumor immunity, making it a potential target for cancer immunotherapy. Recombinant CD58 proteins have become important tools for studying this pathway, providing insights into its structure, function, and potential therapeutic applications. By generating CD58 in a recombinant form, researchers can investigate its interactions, mechanisms of action, and role in enhancing or inhibiting immune responses. Moreover, the engineering of CD58-based vaccines or immune modulators could lead to novel therapeutic strategies for treating cancers and other diseases characterized by immune dysregulation. Thus, the study of CD58 recombinant proteins not only enhances our understanding of immune interactions but also paves the way for innovative approaches in immunotherapy and vaccine development.
